[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:aqp4-gene":3},{"name":4,"total":5,"recruiting":6,"trials":7},"AQP4 Gene",5,3,[8,16,22,28,36],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05199688","A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)",[12],"Phase 3","RECRUITING","2026-08-26T02:17:29.353236Z","2026-05-05T02:43:27.078519Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT05966467","Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies",[],"2026-08-26T02:16:09.452956Z","2026-05-13T02:55:06.396826Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":26,"content_modified":27},"NCT05566769","Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD",[],"2026-08-26T02:18:08.005333Z","2026-05-05T02:43:29.074153Z",{"nct_id":29,"title":30,"phases":31,"status":33,"updated_at":34,"content_modified":35},"NCT07573332","A Safety and Tolerability Study of CC- 97540 (BMS-086353) in Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Patients",[32],"Phase 1","NOT_YET_RECRUITING","2026-08-26T02:16:24.970704Z","2026-05-13T02:55:06.779291Z",{"nct_id":37,"title":38,"phases":39,"status":41,"updated_at":42,"content_modified":43},"NCT05346354","Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD",[40],"Phase 2\u002FPhase 3","ACTIVE_NOT_RECRUITING","2026-08-03T03:14:40.336483Z","2026-05-05T02:43:27.415428Z"]